What is Caladrius Biosciences, Inc.'s current stock price?

Caladrius Biosciences, Inc. (CLBS) currently trades at USD 0.4264. Track real-time price changes and historical performance on AllInvestView.

What sector is Caladrius Biosciences, Inc. in?

Caladrius Biosciences, Inc. operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Caladrius Biosciences, Inc. CLBS · Stock Open Caladrius Biosciences, Inc. in new tab

0.4264 USD

Add to portfolio

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Caladrius Biosciences, Inc. (CLBS)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Caladrius Biosciences, Inc. Analysis (CLBS)

United States Health Care Official Website Stock

Is Caladrius Biosciences, Inc. a good investment? Caladrius Biosciences, Inc. (CLBS) is currently trading at 0.4264 USD.

Investor FAQ

Does Caladrius Biosciences, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Caladrius Biosciences, Inc.?

Caladrius Biosciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Exchange Ticker

NMS (United States) CLBS

Trades

Dividend History paid per year (USD)

Historical Dividends

Year	Total Dividends
▸2013	0.00 USD
Oct. 28, 2013	0.0021
▸2011	0.00 USD
April 4, 2011	0.0002

Caladrius Biosciences, Inc. CLBS · Stock Open Caladrius Biosciences, Inc. in new tab

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Caladrius Biosciences, Inc. Analysis (CLBS)

Investor FAQ

Company Profile

Fundamentals

Under Construction

Caladrius Biosciences, Inc. CLBS · Stock Open Caladrius Biosciences, Inc. in new tab

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Caladrius Biosciences, Inc. Analysis (CLBS)

Investor FAQ

Company Profile

Explore Premium Features

Fundamentals

Under Construction

Community Discussion

Notifications